nodes	percent_of_prediction	percent_of_DWPC	metapath
Propranolol—ADRB3—polycystic ovary syndrome	0.453	0.586	CbGaD
Propranolol—ADRB2—polycystic ovary syndrome	0.172	0.223	CbGaD
Propranolol—CYP1A1—polycystic ovary syndrome	0.148	0.191	CbGaD
Propranolol—SLC22A2—Metformin—polycystic ovary syndrome	0.0726	1	CbGbCtD
Propranolol—CYP2C19—urine—polycystic ovary syndrome	0.00191	0.108	CbGeAlD
Propranolol—CYP1A2—urine—polycystic ovary syndrome	0.00156	0.0884	CbGeAlD
Propranolol—ADRB3—adipose tissue—polycystic ovary syndrome	0.00124	0.0705	CbGeAlD
Propranolol—CYP3A4—urine—polycystic ovary syndrome	0.00113	0.064	CbGeAlD
Propranolol—CYP2D6—urine—polycystic ovary syndrome	0.00111	0.063	CbGeAlD
Propranolol—ADRB3—female gonad—polycystic ovary syndrome	0.00104	0.059	CbGeAlD
Propranolol—CYP3A7—endocrine gland—polycystic ovary syndrome	0.000709	0.0402	CbGeAlD
Propranolol—ORM1—endometrium—polycystic ovary syndrome	0.00064	0.0363	CbGeAlD
Propranolol—Bopindolol—ADRB3—polycystic ovary syndrome	0.000604	0.075	CrCbGaD
Propranolol—Terbinafine—CYP11A1—polycystic ovary syndrome	0.000518	0.0643	CrCbGaD
Propranolol—ADRB1—adipose tissue—polycystic ovary syndrome	0.000509	0.0288	CbGeAlD
Propranolol—Alprenolol—ADRB3—polycystic ovary syndrome	0.000483	0.06	CrCbGaD
Propranolol—ORM1—endocrine gland—polycystic ovary syndrome	0.000449	0.0254	CbGeAlD
Propranolol—HTR1B—endocrine gland—polycystic ovary syndrome	0.000421	0.0238	CbGeAlD
Propranolol—Bevantolol—ADRA1A—polycystic ovary syndrome	0.000417	0.0518	CrCbGaD
Propranolol—Pindolol—ADRB3—polycystic ovary syndrome	0.000415	0.0516	CrCbGaD
Propranolol—ADRB1—endocrine gland—polycystic ovary syndrome	0.000396	0.0224	CbGeAlD
Propranolol—HTR1A—adrenal gland—polycystic ovary syndrome	0.000391	0.0222	CbGeAlD
Propranolol—Naphazoline—ADRA1A—polycystic ovary syndrome	0.000386	0.048	CrCbGaD
Propranolol—HTR1A—endocrine gland—polycystic ovary syndrome	0.000339	0.0192	CbGeAlD
Propranolol—CYP2C19—vagina—polycystic ovary syndrome	0.000339	0.0192	CbGeAlD
Propranolol—CYP1A1—uterus—polycystic ovary syndrome	0.000335	0.019	CbGeAlD
Propranolol—Carvedilol—ADRA1D—polycystic ovary syndrome	0.000332	0.0412	CrCbGaD
Propranolol—Levobunolol—ADRB2—polycystic ovary syndrome	0.000331	0.0412	CrCbGaD
Propranolol—CYP1A1—adipose tissue—polycystic ovary syndrome	0.000328	0.0186	CbGeAlD
Propranolol—CYP3A5—adipose tissue—polycystic ovary syndrome	0.000321	0.0182	CbGeAlD
Propranolol—CYP2C19—endocrine gland—polycystic ovary syndrome	0.000317	0.0179	CbGeAlD
Propranolol—Metipranolol—ADRB2—polycystic ovary syndrome	0.000316	0.0393	CrCbGaD
Propranolol—Carvedilol—ADRB3—polycystic ovary syndrome	0.000298	0.037	CrCbGaD
Propranolol—Carvedilol—ADRA1B—polycystic ovary syndrome	0.000283	0.0352	CrCbGaD
Propranolol—Carteolol—ADRB2—polycystic ovary syndrome	0.000282	0.035	CrCbGaD
Propranolol—CYP1A1—female gonad—polycystic ovary syndrome	0.000274	0.0155	CbGeAlD
Propranolol—CYP1A1—vagina—polycystic ovary syndrome	0.000273	0.0155	CbGeAlD
Propranolol—CYP3A5—female gonad—polycystic ovary syndrome	0.000268	0.0152	CbGeAlD
Propranolol—Terbinafine—CYP19A1—polycystic ovary syndrome	0.000268	0.0333	CrCbGaD
Propranolol—CYP3A5—vagina—polycystic ovary syndrome	0.000267	0.0151	CbGeAlD
Propranolol—CYP1A2—endocrine gland—polycystic ovary syndrome	0.000259	0.0147	CbGeAlD
Propranolol—ABCB1—embryo—polycystic ovary syndrome	0.000258	0.0146	CbGeAlD
Propranolol—CYP1A1—endocrine gland—polycystic ovary syndrome	0.000255	0.0145	CbGeAlD
Propranolol—Esmolol—ADRB2—polycystic ovary syndrome	0.000251	0.0312	CrCbGaD
Propranolol—CYP3A5—endocrine gland—polycystic ovary syndrome	0.00025	0.0141	CbGeAlD
Propranolol—Bevantolol—ADRB2—polycystic ovary syndrome	0.000248	0.0308	CrCbGaD
Propranolol—Bopindolol—ADRB2—polycystic ovary syndrome	0.00023	0.0285	CrCbGaD
Propranolol—Betaxolol—ADRB2—polycystic ovary syndrome	0.000221	0.0275	CrCbGaD
Propranolol—Atenolol—ADRB2—polycystic ovary syndrome	0.000219	0.0272	CrCbGaD
Propranolol—Penbutolol—ADRB2—polycystic ovary syndrome	0.000219	0.0272	CrCbGaD
Propranolol—Bisoprolol—ADRB2—polycystic ovary syndrome	0.000214	0.0265	CrCbGaD
Propranolol—ABCB1—adrenal cortex—polycystic ovary syndrome	0.000212	0.012	CbGeAlD
Propranolol—Acebutolol—ADRB2—polycystic ovary syndrome	0.000202	0.0251	CrCbGaD
Propranolol—Carvedilol—VEGFA—polycystic ovary syndrome	0.000201	0.025	CrCbGaD
Propranolol—Oxprenolol—ADRB2—polycystic ovary syndrome	0.000201	0.0249	CrCbGaD
Propranolol—CYP2D6—female gonad—polycystic ovary syndrome	0.000198	0.0112	CbGeAlD
Propranolol—Carvedilol—ADRA1A—polycystic ovary syndrome	0.000191	0.0237	CrCbGaD
Propranolol—ABCB1—endometrium—polycystic ovary syndrome	0.000189	0.0107	CbGeAlD
Propranolol—CYP3A4—endocrine gland—polycystic ovary syndrome	0.000187	0.0106	CbGeAlD
Propranolol—CYP2D6—endocrine gland—polycystic ovary syndrome	0.000184	0.0104	CbGeAlD
Propranolol—Alprenolol—ADRB2—polycystic ovary syndrome	0.000184	0.0228	CrCbGaD
Propranolol—ABCB1—uterus—polycystic ovary syndrome	0.000174	0.00987	CbGeAlD
Propranolol—ABCB1—pituitary gland—polycystic ovary syndrome	0.000171	0.00969	CbGeAlD
Propranolol—Metoprolol—ADRB2—polycystic ovary syndrome	0.000171	0.0212	CrCbGaD
Propranolol—ABCB1—adipose tissue—polycystic ovary syndrome	0.00017	0.00965	CbGeAlD
Propranolol—Pindolol—ADRB2—polycystic ovary syndrome	0.000158	0.0196	CrCbGaD
Propranolol—ABCB1—adrenal gland—polycystic ovary syndrome	0.000153	0.00866	CbGeAlD
Propranolol—Respiratory distress—Metformin—polycystic ovary syndrome	0.000149	0.117	CcSEcCtD
Propranolol—ABCB1—female gonad—polycystic ovary syndrome	0.000143	0.00808	CbGeAlD
Propranolol—ABCB1—vagina—polycystic ovary syndrome	0.000142	0.00803	CbGeAlD
Propranolol—ABCB1—endocrine gland—polycystic ovary syndrome	0.000133	0.00751	CbGeAlD
Propranolol—Carvedilol—ADRB2—polycystic ovary syndrome	0.000113	0.0141	CrCbGaD
Propranolol—Carvedilol—CYP1A1—polycystic ovary syndrome	9.72e-05	0.0121	CrCbGaD
Propranolol—Lightheadedness—Metformin—polycystic ovary syndrome	8.48e-05	0.0664	CcSEcCtD
Propranolol—Hypoglycaemia—Metformin—polycystic ovary syndrome	7.05e-05	0.0552	CcSEcCtD
Propranolol—Lethargy—Metformin—polycystic ovary syndrome	7.02e-05	0.055	CcSEcCtD
Propranolol—Neutropenia—Metformin—polycystic ovary syndrome	5.56e-05	0.0435	CcSEcCtD
Propranolol—Infestation NOS—Metformin—polycystic ovary syndrome	5.3e-05	0.0415	CcSEcCtD
Propranolol—Infestation—Metformin—polycystic ovary syndrome	5.3e-05	0.0415	CcSEcCtD
Propranolol—Bradycardia—Metformin—polycystic ovary syndrome	4.85e-05	0.0379	CcSEcCtD
Propranolol—Cardiac disorder—Metformin—polycystic ovary syndrome	4.42e-05	0.0346	CcSEcCtD
Propranolol—Erythema—Metformin—polycystic ovary syndrome	4.15e-05	0.0324	CcSEcCtD
Propranolol—Unspecified disorder of skin and subcutaneous tissue—Metformin—polycystic ovary syndrome	3.5e-05	0.0274	CcSEcCtD
Propranolol—Infection—Metformin—polycystic ovary syndrome	3.36e-05	0.0263	CcSEcCtD
Propranolol—Nervous system disorder—Metformin—polycystic ovary syndrome	3.32e-05	0.026	CcSEcCtD
Propranolol—Skin disorder—Metformin—polycystic ovary syndrome	3.29e-05	0.0257	CcSEcCtD
Propranolol—Paraesthesia—Metformin—polycystic ovary syndrome	3.04e-05	0.0238	CcSEcCtD
Propranolol—Dyspnoea—Metformin—polycystic ovary syndrome	3.02e-05	0.0236	CcSEcCtD
Propranolol—Somnolence—Metformin—polycystic ovary syndrome	3.01e-05	0.0235	CcSEcCtD
Propranolol—Dyspepsia—Metformin—polycystic ovary syndrome	2.98e-05	0.0233	CcSEcCtD
Propranolol—Decreased appetite—Metformin—polycystic ovary syndrome	2.94e-05	0.023	CcSEcCtD
Propranolol—Gastrointestinal disorder—Metformin—polycystic ovary syndrome	2.92e-05	0.0229	CcSEcCtD
Propranolol—Fatigue—Metformin—polycystic ovary syndrome	2.92e-05	0.0228	CcSEcCtD
Propranolol—Constipation—Metformin—polycystic ovary syndrome	2.89e-05	0.0226	CcSEcCtD
Propranolol—Gastrointestinal pain—Metformin—polycystic ovary syndrome	2.77e-05	0.0216	CcSEcCtD
Propranolol—Urticaria—Metformin—polycystic ovary syndrome	2.69e-05	0.021	CcSEcCtD
Propranolol—Abdominal pain—Metformin—polycystic ovary syndrome	2.67e-05	0.0209	CcSEcCtD
Propranolol—Asthenia—Metformin—polycystic ovary syndrome	2.43e-05	0.019	CcSEcCtD
Propranolol—Diarrhoea—Metformin—polycystic ovary syndrome	2.31e-05	0.0181	CcSEcCtD
Propranolol—Dizziness—Metformin—polycystic ovary syndrome	2.24e-05	0.0175	CcSEcCtD
Propranolol—Vomiting—Metformin—polycystic ovary syndrome	2.15e-05	0.0168	CcSEcCtD
Propranolol—Rash—Metformin—polycystic ovary syndrome	2.13e-05	0.0167	CcSEcCtD
Propranolol—Dermatitis—Metformin—polycystic ovary syndrome	2.13e-05	0.0167	CcSEcCtD
Propranolol—Nausea—Metformin—polycystic ovary syndrome	2.01e-05	0.0157	CcSEcCtD
Propranolol—CYP2C19—Metabolism—LHB—polycystic ovary syndrome	1.09e-05	8.63e-05	CbGpPWpGaD
Propranolol—HTR1B—Signaling Pathways—GNAS—polycystic ovary syndrome	1.09e-05	8.62e-05	CbGpPWpGaD
Propranolol—ADRB1—GPCR downstream signaling—POMC—polycystic ovary syndrome	1.09e-05	8.61e-05	CbGpPWpGaD
Propranolol—CYP3A5—Metabolism—CYP11A1—polycystic ovary syndrome	1.09e-05	8.61e-05	CbGpPWpGaD
Propranolol—CYP1A1—Metabolism—YAP1—polycystic ovary syndrome	1.09e-05	8.57e-05	CbGpPWpGaD
Propranolol—CYP1A2—Metabolism of lipids and lipoproteins—CYP19A1—polycystic ovary syndrome	1.09e-05	8.57e-05	CbGpPWpGaD
Propranolol—HTR1A—Signaling Pathways—GHRL—polycystic ovary syndrome	1.08e-05	8.55e-05	CbGpPWpGaD
Propranolol—HTR1A—Signaling Pathways—PLAT—polycystic ovary syndrome	1.08e-05	8.55e-05	CbGpPWpGaD
Propranolol—ADRB1—Signaling Pathways—ATF1—polycystic ovary syndrome	1.08e-05	8.53e-05	CbGpPWpGaD
Propranolol—CYP2C19—Metabolism—HSD3B2—polycystic ovary syndrome	1.07e-05	8.43e-05	CbGpPWpGaD
Propranolol—ADRB2—GPCR downstream signaling—POMC—polycystic ovary syndrome	1.07e-05	8.43e-05	CbGpPWpGaD
Propranolol—ABCB1—Metabolism—LHB—polycystic ovary syndrome	1.07e-05	8.42e-05	CbGpPWpGaD
Propranolol—ADRB2—Signaling Pathways—ATF1—polycystic ovary syndrome	1.06e-05	8.34e-05	CbGpPWpGaD
Propranolol—ADRB1—Signaling Pathways—TCF7L2—polycystic ovary syndrome	1.05e-05	8.32e-05	CbGpPWpGaD
Propranolol—ADRB1—GPCR downstream signaling—AKT2—polycystic ovary syndrome	1.05e-05	8.28e-05	CbGpPWpGaD
Propranolol—HTR1A—GPCR downstream signaling—POMC—polycystic ovary syndrome	1.04e-05	8.24e-05	CbGpPWpGaD
Propranolol—CYP1A1—Metabolism—NAMPT—polycystic ovary syndrome	1.04e-05	8.24e-05	CbGpPWpGaD
Propranolol—ABCB1—Metabolism—HSD3B2—polycystic ovary syndrome	1.04e-05	8.23e-05	CbGpPWpGaD
Propranolol—HTR1B—Signaling Pathways—NCOR1—polycystic ovary syndrome	1.04e-05	8.21e-05	CbGpPWpGaD
Propranolol—CYP1A1—Metabolism of lipids and lipoproteins—PPARG—polycystic ovary syndrome	1.04e-05	8.19e-05	CbGpPWpGaD
Propranolol—CYP2C19—Metabolism—AKR1C1—polycystic ovary syndrome	1.03e-05	8.17e-05	CbGpPWpGaD
Propranolol—HTR1A—Signaling Pathways—ATF1—polycystic ovary syndrome	1.03e-05	8.16e-05	CbGpPWpGaD
Propranolol—ADRB2—Signaling Pathways—TCF7L2—polycystic ovary syndrome	1.03e-05	8.14e-05	CbGpPWpGaD
Propranolol—CYP1A1—Metabolism—CYP11A1—polycystic ovary syndrome	1.03e-05	8.13e-05	CbGpPWpGaD
Propranolol—CYP3A5—Metabolism—AKR1C3—polycystic ovary syndrome	1.03e-05	8.13e-05	CbGpPWpGaD
Propranolol—ADRB2—GPCR downstream signaling—AKT2—polycystic ovary syndrome	1.03e-05	8.1e-05	CbGpPWpGaD
Propranolol—ADRB3—Signaling Pathways—IRS1—polycystic ovary syndrome	1.02e-05	8.08e-05	CbGpPWpGaD
Propranolol—CYP1A1—Metabolism of lipids and lipoproteins—POMC—polycystic ovary syndrome	1.02e-05	8.08e-05	CbGpPWpGaD
Propranolol—HTR1B—Signaling Pathways—NRG1—polycystic ovary syndrome	1.02e-05	8.06e-05	CbGpPWpGaD
Propranolol—CYP3A5—Metabolism—CYP17A1—polycystic ovary syndrome	1.01e-05	8e-05	CbGpPWpGaD
Propranolol—ABCB1—Metabolism—AKR1C1—polycystic ovary syndrome	1.01e-05	7.97e-05	CbGpPWpGaD
Propranolol—HTR1A—Signaling Pathways—TCF7L2—polycystic ovary syndrome	1.01e-05	7.96e-05	CbGpPWpGaD
Propranolol—CYP2D6—Metabolism—LHB—polycystic ovary syndrome	1.01e-05	7.93e-05	CbGpPWpGaD
Propranolol—HTR1A—GPCR downstream signaling—AKT2—polycystic ovary syndrome	1e-05	7.92e-05	CbGpPWpGaD
Propranolol—ADRB1—Signaling Pathways—NGFR—polycystic ovary syndrome	9.98e-06	7.87e-05	CbGpPWpGaD
Propranolol—CYP3A7—Metabolism—GNAS—polycystic ovary syndrome	9.91e-06	7.82e-05	CbGpPWpGaD
Propranolol—ADRB1—Signaling by GPCR—POMC—polycystic ovary syndrome	9.91e-06	7.82e-05	CbGpPWpGaD
Propranolol—SLC22A2—Metabolism—GNAS—polycystic ovary syndrome	9.9e-06	7.81e-05	CbGpPWpGaD
Propranolol—ADRB1—Signaling Pathways—PRL—polycystic ovary syndrome	9.89e-06	7.8e-05	CbGpPWpGaD
Propranolol—ADRB3—Signaling Pathways—POMC—polycystic ovary syndrome	9.87e-06	7.78e-05	CbGpPWpGaD
Propranolol—CYP2D6—Metabolism—HSD3B2—polycystic ovary syndrome	9.83e-06	7.75e-05	CbGpPWpGaD
Propranolol—ADRB3—Signaling Pathways—INS—polycystic ovary syndrome	9.81e-06	7.74e-05	CbGpPWpGaD
Propranolol—CYP1A2—Metabolism—HMMR—polycystic ovary syndrome	9.79e-06	7.73e-05	CbGpPWpGaD
Propranolol—ADRB2—Signaling Pathways—NGFR—polycystic ovary syndrome	9.76e-06	7.7e-05	CbGpPWpGaD
Propranolol—CYP1A1—Metabolism—AKR1C3—polycystic ovary syndrome	9.74e-06	7.68e-05	CbGpPWpGaD
Propranolol—ADRB2—Signaling by GPCR—POMC—polycystic ovary syndrome	9.7e-06	7.65e-05	CbGpPWpGaD
Propranolol—ADRB2—Signaling Pathways—PRL—polycystic ovary syndrome	9.67e-06	7.63e-05	CbGpPWpGaD
Propranolol—CYP1A1—Metabolism—CYP17A1—polycystic ovary syndrome	9.58e-06	7.56e-05	CbGpPWpGaD
Propranolol—HTR1A—Signaling Pathways—NGFR—polycystic ovary syndrome	9.54e-06	7.53e-05	CbGpPWpGaD
Propranolol—ADRB1—Signaling by GPCR—AKT2—polycystic ovary syndrome	9.53e-06	7.52e-05	CbGpPWpGaD
Propranolol—CYP2C19—Metabolism—SULT2A1—polycystic ovary syndrome	9.52e-06	7.51e-05	CbGpPWpGaD
Propranolol—CYP2D6—Metabolism—AKR1C1—polycystic ovary syndrome	9.52e-06	7.51e-05	CbGpPWpGaD
Propranolol—ADRB3—Signaling Pathways—IGF1—polycystic ovary syndrome	9.49e-06	7.49e-05	CbGpPWpGaD
Propranolol—ADRB3—Signaling Pathways—AKT2—polycystic ovary syndrome	9.48e-06	7.48e-05	CbGpPWpGaD
Propranolol—HTR1A—Signaling by GPCR—POMC—polycystic ovary syndrome	9.48e-06	7.48e-05	CbGpPWpGaD
Propranolol—HTR1A—Signaling Pathways—PRL—polycystic ovary syndrome	9.46e-06	7.46e-05	CbGpPWpGaD
Propranolol—CYP3A7—Metabolism—NCOR1—polycystic ovary syndrome	9.44e-06	7.45e-05	CbGpPWpGaD
Propranolol—SLC22A2—Metabolism—NCOR1—polycystic ovary syndrome	9.43e-06	7.44e-05	CbGpPWpGaD
Propranolol—ADRB1—Signaling Pathways—ADRB2—polycystic ovary syndrome	9.38e-06	7.4e-05	CbGpPWpGaD
Propranolol—CYP3A4—Metabolism—PNPLA2—polycystic ovary syndrome	9.38e-06	7.4e-05	CbGpPWpGaD
Propranolol—CYP1A2—Metabolism—HSD3B1—polycystic ovary syndrome	9.34e-06	7.37e-05	CbGpPWpGaD
Propranolol—ADRB2—Signaling by GPCR—AKT2—polycystic ovary syndrome	9.32e-06	7.35e-05	CbGpPWpGaD
Propranolol—ABCB1—Metabolism—SULT2A1—polycystic ovary syndrome	9.3e-06	7.33e-05	CbGpPWpGaD
Propranolol—CYP1A2—Metabolism of lipids and lipoproteins—NCOR1—polycystic ovary syndrome	9.23e-06	7.29e-05	CbGpPWpGaD
Propranolol—CYP2C19—Metabolism—RRM2—polycystic ovary syndrome	9.22e-06	7.28e-05	CbGpPWpGaD
Propranolol—HTR1A—Signaling by GPCR—AKT2—polycystic ovary syndrome	9.11e-06	7.19e-05	CbGpPWpGaD
Propranolol—ADRB3—Signaling Pathways—SERPINE1—polycystic ovary syndrome	9.01e-06	7.11e-05	CbGpPWpGaD
Propranolol—ABCB1—Metabolism—RRM2—polycystic ovary syndrome	9e-06	7.1e-05	CbGpPWpGaD
Propranolol—HTR1A—Signaling Pathways—ADRB2—polycystic ovary syndrome	8.97e-06	7.08e-05	CbGpPWpGaD
Propranolol—CYP3A7—Metabolism—CYP1A1—polycystic ovary syndrome	8.95e-06	7.06e-05	CbGpPWpGaD
Propranolol—SLC22A2—Metabolism—CYP1A1—polycystic ovary syndrome	8.94e-06	7.05e-05	CbGpPWpGaD
Propranolol—CYP2C19—Metabolism—YAP1—polycystic ovary syndrome	8.89e-06	7.02e-05	CbGpPWpGaD
Propranolol—CYP3A4—Metabolism—SRD5A1—polycystic ovary syndrome	8.89e-06	7.01e-05	CbGpPWpGaD
Propranolol—CYP3A5—Metabolism—TH—polycystic ovary syndrome	8.78e-06	6.93e-05	CbGpPWpGaD
Propranolol—CYP2D6—Metabolism—SULT2A1—polycystic ovary syndrome	8.76e-06	6.91e-05	CbGpPWpGaD
Propranolol—CYP1A2—Metabolism of lipids and lipoproteins—CYP1A1—polycystic ovary syndrome	8.75e-06	6.91e-05	CbGpPWpGaD
Propranolol—HTR1B—Signaling Pathways—IRS2—polycystic ovary syndrome	8.75e-06	6.9e-05	CbGpPWpGaD
Propranolol—ADRB1—Signaling Pathways—GNAS—polycystic ovary syndrome	8.7e-06	6.86e-05	CbGpPWpGaD
Propranolol—ABCB1—Metabolism—YAP1—polycystic ovary syndrome	8.68e-06	6.85e-05	CbGpPWpGaD
Propranolol—HTR1B—Signaling Pathways—LEP—polycystic ovary syndrome	8.56e-06	6.75e-05	CbGpPWpGaD
Propranolol—CYP2C19—Metabolism—NAMPT—polycystic ovary syndrome	8.54e-06	6.74e-05	CbGpPWpGaD
Propranolol—CYP3A5—Metabolism—SLC2A4—polycystic ovary syndrome	8.54e-06	6.74e-05	CbGpPWpGaD
Propranolol—CYP1A2—Metabolism—LHB—polycystic ovary syndrome	8.52e-06	6.72e-05	CbGpPWpGaD
Propranolol—ADRB2—Signaling Pathways—GNAS—polycystic ovary syndrome	8.51e-06	6.71e-05	CbGpPWpGaD
Propranolol—CYP2C19—Metabolism of lipids and lipoproteins—PPARG—polycystic ovary syndrome	8.49e-06	6.7e-05	CbGpPWpGaD
Propranolol—CYP2D6—Metabolism—RRM2—polycystic ovary syndrome	8.48e-06	6.69e-05	CbGpPWpGaD
Propranolol—CYP3A4—Metabolism—STAR—polycystic ovary syndrome	8.48e-06	6.69e-05	CbGpPWpGaD
Propranolol—CYP2C19—Metabolism—CYP11A1—polycystic ovary syndrome	8.44e-06	6.66e-05	CbGpPWpGaD
Propranolol—CYP2C19—Metabolism of lipids and lipoproteins—POMC—polycystic ovary syndrome	8.38e-06	6.61e-05	CbGpPWpGaD
Propranolol—CYP3A7—Metabolism—MTHFR—polycystic ovary syndrome	8.35e-06	6.58e-05	CbGpPWpGaD
Propranolol—ABCB1—Metabolism—NAMPT—polycystic ovary syndrome	8.34e-06	6.58e-05	CbGpPWpGaD
Propranolol—SLC22A2—Metabolism—MTHFR—polycystic ovary syndrome	8.33e-06	6.57e-05	CbGpPWpGaD
Propranolol—CYP1A2—Metabolism—HSD3B2—polycystic ovary syndrome	8.33e-06	6.57e-05	CbGpPWpGaD
Propranolol—HTR1A—Signaling Pathways—GNAS—polycystic ovary syndrome	8.32e-06	6.56e-05	CbGpPWpGaD
Propranolol—CYP1A1—Metabolism—TH—polycystic ovary syndrome	8.29e-06	6.54e-05	CbGpPWpGaD
Propranolol—ADRB1—Signaling Pathways—NCOR1—polycystic ovary syndrome	8.29e-06	6.54e-05	CbGpPWpGaD
Propranolol—ABCB1—Metabolism—CYP11A1—polycystic ovary syndrome	8.23e-06	6.5e-05	CbGpPWpGaD
Propranolol—CYP2D6—Metabolism—YAP1—polycystic ovary syndrome	8.18e-06	6.45e-05	CbGpPWpGaD
Propranolol—ADRB1—Signaling Pathways—NRG1—polycystic ovary syndrome	8.13e-06	6.42e-05	CbGpPWpGaD
Propranolol—ADRB2—Signaling Pathways—NCOR1—polycystic ovary syndrome	8.1e-06	6.39e-05	CbGpPWpGaD
Propranolol—CYP1A1—Metabolism—SLC2A4—polycystic ovary syndrome	8.07e-06	6.36e-05	CbGpPWpGaD
Propranolol—CYP1A2—Metabolism—AKR1C1—polycystic ovary syndrome	8.06e-06	6.36e-05	CbGpPWpGaD
Propranolol—CYP3A5—Metabolism—CYP19A1—polycystic ovary syndrome	8.03e-06	6.33e-05	CbGpPWpGaD
Propranolol—CYP2C19—Metabolism—AKR1C3—polycystic ovary syndrome	7.97e-06	6.29e-05	CbGpPWpGaD
Propranolol—ADRB2—Signaling Pathways—NRG1—polycystic ovary syndrome	7.96e-06	6.28e-05	CbGpPWpGaD
Propranolol—HTR1A—Signaling Pathways—NCOR1—polycystic ovary syndrome	7.92e-06	6.25e-05	CbGpPWpGaD
Propranolol—CYP2D6—Metabolism—NAMPT—polycystic ovary syndrome	7.86e-06	6.2e-05	CbGpPWpGaD
Propranolol—CYP2C19—Metabolism—CYP17A1—polycystic ovary syndrome	7.84e-06	6.19e-05	CbGpPWpGaD
Propranolol—HTR1A—Signaling Pathways—NRG1—polycystic ovary syndrome	7.78e-06	6.14e-05	CbGpPWpGaD
Propranolol—ABCB1—Metabolism—AKR1C3—polycystic ovary syndrome	7.78e-06	6.14e-05	CbGpPWpGaD
Propranolol—CYP2D6—Metabolism—CYP11A1—polycystic ovary syndrome	7.76e-06	6.12e-05	CbGpPWpGaD
Propranolol—ABCB1—Metabolism—CYP17A1—polycystic ovary syndrome	7.65e-06	6.04e-05	CbGpPWpGaD
Propranolol—HTR1B—Signaling Pathways—IRS1—polycystic ovary syndrome	7.64e-06	6.02e-05	CbGpPWpGaD
Propranolol—CYP1A1—Metabolism—CYP19A1—polycystic ovary syndrome	7.58e-06	5.98e-05	CbGpPWpGaD
Propranolol—CYP3A4—Metabolism—HMMR—polycystic ovary syndrome	7.56e-06	5.96e-05	CbGpPWpGaD
Propranolol—CYP1A2—Metabolism—SULT2A1—polycystic ovary syndrome	7.42e-06	5.85e-05	CbGpPWpGaD
Propranolol—HTR1B—Signaling Pathways—POMC—polycystic ovary syndrome	7.35e-06	5.8e-05	CbGpPWpGaD
Propranolol—CYP2D6—Metabolism—AKR1C3—polycystic ovary syndrome	7.33e-06	5.78e-05	CbGpPWpGaD
Propranolol—HTR1B—Signaling Pathways—INS—polycystic ovary syndrome	7.31e-06	5.77e-05	CbGpPWpGaD
Propranolol—ADRB3—Signaling by GPCR—IL6—polycystic ovary syndrome	7.26e-06	5.73e-05	CbGpPWpGaD
Propranolol—CYP2D6—Metabolism—CYP17A1—polycystic ovary syndrome	7.21e-06	5.69e-05	CbGpPWpGaD
Propranolol—CYP3A4—Metabolism—HSD3B1—polycystic ovary syndrome	7.21e-06	5.69e-05	CbGpPWpGaD
Propranolol—CYP1A2—Metabolism—RRM2—polycystic ovary syndrome	7.19e-06	5.67e-05	CbGpPWpGaD
Propranolol—CYP3A5—Metabolism—GNAS—polycystic ovary syndrome	7.17e-06	5.65e-05	CbGpPWpGaD
Propranolol—HTR1B—Signaling Pathways—IGF1—polycystic ovary syndrome	7.07e-06	5.58e-05	CbGpPWpGaD
Propranolol—HTR1B—Signaling Pathways—AKT2—polycystic ovary syndrome	7.07e-06	5.58e-05	CbGpPWpGaD
Propranolol—ADRB1—Signaling Pathways—IRS2—polycystic ovary syndrome	6.97e-06	5.5e-05	CbGpPWpGaD
Propranolol—CYP1A2—Metabolism—YAP1—polycystic ovary syndrome	6.93e-06	5.47e-05	CbGpPWpGaD
Propranolol—CYP3A5—Metabolism—NCOR1—polycystic ovary syndrome	6.83e-06	5.39e-05	CbGpPWpGaD
Propranolol—ADRB1—Signaling Pathways—LEP—polycystic ovary syndrome	6.82e-06	5.38e-05	CbGpPWpGaD
Propranolol—ADRB2—Signaling Pathways—IRS2—polycystic ovary syndrome	6.81e-06	5.38e-05	CbGpPWpGaD
Propranolol—CYP2C19—Metabolism—TH—polycystic ovary syndrome	6.79e-06	5.35e-05	CbGpPWpGaD
Propranolol—CYP1A1—Metabolism—GNAS—polycystic ovary syndrome	6.77e-06	5.34e-05	CbGpPWpGaD
Propranolol—CYP3A7—Metabolism—PPARG—polycystic ovary syndrome	6.77e-06	5.34e-05	CbGpPWpGaD
Propranolol—SLC22A2—Metabolism—PPARG—polycystic ovary syndrome	6.76e-06	5.33e-05	CbGpPWpGaD
Propranolol—HTR1B—Signaling Pathways—SERPINE1—polycystic ovary syndrome	6.72e-06	5.3e-05	CbGpPWpGaD
Propranolol—CYP3A7—Metabolism—POMC—polycystic ovary syndrome	6.67e-06	5.27e-05	CbGpPWpGaD
Propranolol—ADRB2—Signaling Pathways—LEP—polycystic ovary syndrome	6.67e-06	5.26e-05	CbGpPWpGaD
Propranolol—SLC22A2—Metabolism—POMC—polycystic ovary syndrome	6.66e-06	5.26e-05	CbGpPWpGaD
Propranolol—HTR1A—Signaling Pathways—IRS2—polycystic ovary syndrome	6.66e-06	5.26e-05	CbGpPWpGaD
Propranolol—CYP1A2—Metabolism—NAMPT—polycystic ovary syndrome	6.66e-06	5.25e-05	CbGpPWpGaD
Propranolol—CYP3A7—Metabolism—INS—polycystic ovary syndrome	6.64e-06	5.24e-05	CbGpPWpGaD
Propranolol—SLC22A2—Metabolism—INS—polycystic ovary syndrome	6.63e-06	5.23e-05	CbGpPWpGaD
Propranolol—ABCB1—Metabolism—TH—polycystic ovary syndrome	6.62e-06	5.23e-05	CbGpPWpGaD
Propranolol—CYP1A2—Metabolism of lipids and lipoproteins—PPARG—polycystic ovary syndrome	6.62e-06	5.22e-05	CbGpPWpGaD
Propranolol—CYP2C19—Metabolism—SLC2A4—polycystic ovary syndrome	6.6e-06	5.21e-05	CbGpPWpGaD
Propranolol—CYP3A4—Metabolism—LHB—polycystic ovary syndrome	6.57e-06	5.19e-05	CbGpPWpGaD
Propranolol—CYP1A2—Metabolism—CYP11A1—polycystic ovary syndrome	6.57e-06	5.19e-05	CbGpPWpGaD
Propranolol—CYP1A2—Metabolism of lipids and lipoproteins—POMC—polycystic ovary syndrome	6.53e-06	5.15e-05	CbGpPWpGaD
Propranolol—HTR1A—Signaling Pathways—LEP—polycystic ovary syndrome	6.52e-06	5.14e-05	CbGpPWpGaD
Propranolol—CYP3A5—Metabolism—CYP1A1—polycystic ovary syndrome	6.47e-06	5.11e-05	CbGpPWpGaD
Propranolol—CYP1A1—Metabolism—NCOR1—polycystic ovary syndrome	6.45e-06	5.09e-05	CbGpPWpGaD
Propranolol—ABCB1—Metabolism—SLC2A4—polycystic ovary syndrome	6.44e-06	5.08e-05	CbGpPWpGaD
Propranolol—CYP3A4—Metabolism—HSD3B2—polycystic ovary syndrome	6.43e-06	5.07e-05	CbGpPWpGaD
Propranolol—CYP2D6—Metabolism—TH—polycystic ovary syndrome	6.24e-06	4.92e-05	CbGpPWpGaD
Propranolol—CYP3A4—Metabolism—AKR1C1—polycystic ovary syndrome	6.22e-06	4.91e-05	CbGpPWpGaD
Propranolol—CYP1A2—Metabolism—AKR1C3—polycystic ovary syndrome	6.21e-06	4.9e-05	CbGpPWpGaD
Propranolol—CYP2C19—Metabolism—CYP19A1—polycystic ovary syndrome	6.21e-06	4.9e-05	CbGpPWpGaD
Propranolol—ADRB3—Signaling Pathways—VEGFA—polycystic ovary syndrome	6.2e-06	4.89e-05	CbGpPWpGaD
Propranolol—CYP1A2—Metabolism—CYP17A1—polycystic ovary syndrome	6.11e-06	4.82e-05	CbGpPWpGaD
Propranolol—ADRB1—Signaling Pathways—IRS1—polycystic ovary syndrome	6.08e-06	4.8e-05	CbGpPWpGaD
Propranolol—CYP2D6—Metabolism—SLC2A4—polycystic ovary syndrome	6.07e-06	4.79e-05	CbGpPWpGaD
Propranolol—ABCB1—Metabolism—CYP19A1—polycystic ovary syndrome	6.06e-06	4.78e-05	CbGpPWpGaD
Propranolol—CYP3A5—Metabolism—MTHFR—polycystic ovary syndrome	6.03e-06	4.76e-05	CbGpPWpGaD
Propranolol—ADRB2—Signaling Pathways—IRS1—polycystic ovary syndrome	5.95e-06	4.69e-05	CbGpPWpGaD
Propranolol—ADRB1—Signaling Pathways—POMC—polycystic ovary syndrome	5.86e-06	4.62e-05	CbGpPWpGaD
Propranolol—ADRB1—Signaling Pathways—INS—polycystic ovary syndrome	5.82e-06	4.59e-05	CbGpPWpGaD
Propranolol—HTR1A—Signaling Pathways—IRS1—polycystic ovary syndrome	5.82e-06	4.59e-05	CbGpPWpGaD
Propranolol—ADRB2—Signaling Pathways—POMC—polycystic ovary syndrome	5.73e-06	4.52e-05	CbGpPWpGaD
Propranolol—CYP3A4—Metabolism—SULT2A1—polycystic ovary syndrome	5.73e-06	4.52e-05	CbGpPWpGaD
Propranolol—CYP2D6—Metabolism—CYP19A1—polycystic ovary syndrome	5.71e-06	4.5e-05	CbGpPWpGaD
Propranolol—CYP1A1—Metabolism—MTHFR—polycystic ovary syndrome	5.7e-06	4.5e-05	CbGpPWpGaD
Propranolol—ADRB2—Signaling Pathways—INS—polycystic ovary syndrome	5.7e-06	4.49e-05	CbGpPWpGaD
Propranolol—ADRB1—Signaling Pathways—IGF1—polycystic ovary syndrome	5.63e-06	4.44e-05	CbGpPWpGaD
Propranolol—ADRB1—Signaling Pathways—AKT2—polycystic ovary syndrome	5.63e-06	4.44e-05	CbGpPWpGaD
Propranolol—HTR1A—Signaling Pathways—POMC—polycystic ovary syndrome	5.6e-06	4.42e-05	CbGpPWpGaD
Propranolol—HTR1A—Signaling Pathways—INS—polycystic ovary syndrome	5.57e-06	4.39e-05	CbGpPWpGaD
Propranolol—CYP3A4—Metabolism—RRM2—polycystic ovary syndrome	5.55e-06	4.38e-05	CbGpPWpGaD
Propranolol—CYP2C19—Metabolism—GNAS—polycystic ovary syndrome	5.54e-06	4.37e-05	CbGpPWpGaD
Propranolol—ADRB2—Signaling Pathways—IGF1—polycystic ovary syndrome	5.51e-06	4.35e-05	CbGpPWpGaD
Propranolol—ADRB2—Signaling Pathways—AKT2—polycystic ovary syndrome	5.51e-06	4.34e-05	CbGpPWpGaD
Propranolol—HTR1B—Signaling by GPCR—IL6—polycystic ovary syndrome	5.41e-06	4.27e-05	CbGpPWpGaD
Propranolol—ABCB1—Metabolism—GNAS—polycystic ovary syndrome	5.41e-06	4.27e-05	CbGpPWpGaD
Propranolol—HTR1A—Signaling Pathways—IGF1—polycystic ovary syndrome	5.39e-06	4.25e-05	CbGpPWpGaD
Propranolol—HTR1A—Signaling Pathways—AKT2—polycystic ovary syndrome	5.38e-06	4.25e-05	CbGpPWpGaD
Propranolol—ADRB1—Signaling Pathways—SERPINE1—polycystic ovary syndrome	5.35e-06	4.22e-05	CbGpPWpGaD
Propranolol—CYP3A4—Metabolism—YAP1—polycystic ovary syndrome	5.35e-06	4.22e-05	CbGpPWpGaD
Propranolol—CYP1A2—Metabolism—TH—polycystic ovary syndrome	5.29e-06	4.17e-05	CbGpPWpGaD
Propranolol—CYP2C19—Metabolism—NCOR1—polycystic ovary syndrome	5.28e-06	4.16e-05	CbGpPWpGaD
Propranolol—ADRB2—Signaling Pathways—SERPINE1—polycystic ovary syndrome	5.23e-06	4.13e-05	CbGpPWpGaD
Propranolol—ABCB1—Metabolism—NCOR1—polycystic ovary syndrome	5.15e-06	4.06e-05	CbGpPWpGaD
Propranolol—CYP1A2—Metabolism—SLC2A4—polycystic ovary syndrome	5.14e-06	4.06e-05	CbGpPWpGaD
Propranolol—CYP3A4—Metabolism—NAMPT—polycystic ovary syndrome	5.14e-06	4.05e-05	CbGpPWpGaD
Propranolol—HTR1A—Signaling Pathways—SERPINE1—polycystic ovary syndrome	5.12e-06	4.04e-05	CbGpPWpGaD
Propranolol—CYP2D6—Metabolism—GNAS—polycystic ovary syndrome	5.1e-06	4.02e-05	CbGpPWpGaD
Propranolol—CYP3A4—Metabolism—CYP11A1—polycystic ovary syndrome	5.07e-06	4e-05	CbGpPWpGaD
Propranolol—CYP2C19—Metabolism—CYP1A1—polycystic ovary syndrome	5e-06	3.95e-05	CbGpPWpGaD
Propranolol—CYP3A5—Metabolism—PPARG—polycystic ovary syndrome	4.89e-06	3.86e-05	CbGpPWpGaD
Propranolol—ABCB1—Metabolism—CYP1A1—polycystic ovary syndrome	4.88e-06	3.85e-05	CbGpPWpGaD
Propranolol—CYP2D6—Metabolism—NCOR1—polycystic ovary syndrome	4.85e-06	3.83e-05	CbGpPWpGaD
Propranolol—CYP1A2—Metabolism—CYP19A1—polycystic ovary syndrome	4.84e-06	3.82e-05	CbGpPWpGaD
Propranolol—CYP3A5—Metabolism—POMC—polycystic ovary syndrome	4.82e-06	3.81e-05	CbGpPWpGaD
Propranolol—CYP3A5—Metabolism—INS—polycystic ovary syndrome	4.8e-06	3.79e-05	CbGpPWpGaD
Propranolol—CYP3A4—Metabolism—AKR1C3—polycystic ovary syndrome	4.79e-06	3.78e-05	CbGpPWpGaD
Propranolol—CYP3A4—Metabolism—CYP17A1—polycystic ovary syndrome	4.72e-06	3.72e-05	CbGpPWpGaD
Propranolol—CYP2C19—Metabolism—MTHFR—polycystic ovary syndrome	4.66e-06	3.68e-05	CbGpPWpGaD
Propranolol—CYP1A1—Metabolism—PPARG—polycystic ovary syndrome	4.62e-06	3.65e-05	CbGpPWpGaD
Propranolol—HTR1B—Signaling Pathways—VEGFA—polycystic ovary syndrome	4.62e-06	3.65e-05	CbGpPWpGaD
Propranolol—CYP2D6—Metabolism—CYP1A1—polycystic ovary syndrome	4.6e-06	3.63e-05	CbGpPWpGaD
Propranolol—CYP1A1—Metabolism—POMC—polycystic ovary syndrome	4.56e-06	3.6e-05	CbGpPWpGaD
Propranolol—ABCB1—Metabolism—MTHFR—polycystic ovary syndrome	4.55e-06	3.59e-05	CbGpPWpGaD
Propranolol—CYP1A1—Metabolism—INS—polycystic ovary syndrome	4.53e-06	3.58e-05	CbGpPWpGaD
Propranolol—CYP1A2—Metabolism—GNAS—polycystic ovary syndrome	4.32e-06	3.41e-05	CbGpPWpGaD
Propranolol—ADRB1—Signaling by GPCR—IL6—polycystic ovary syndrome	4.31e-06	3.4e-05	CbGpPWpGaD
Propranolol—CYP2D6—Metabolism—MTHFR—polycystic ovary syndrome	4.29e-06	3.38e-05	CbGpPWpGaD
Propranolol—ADRB3—Signaling Pathways—IL6—polycystic ovary syndrome	4.29e-06	3.38e-05	CbGpPWpGaD
Propranolol—ADRB2—Signaling by GPCR—IL6—polycystic ovary syndrome	4.21e-06	3.32e-05	CbGpPWpGaD
Propranolol—HTR1A—Signaling by GPCR—IL6—polycystic ovary syndrome	4.12e-06	3.25e-05	CbGpPWpGaD
Propranolol—CYP1A2—Metabolism—NCOR1—polycystic ovary syndrome	4.11e-06	3.24e-05	CbGpPWpGaD
Propranolol—CYP3A4—Metabolism—TH—polycystic ovary syndrome	4.08e-06	3.22e-05	CbGpPWpGaD
Propranolol—CYP3A4—Metabolism—SLC2A4—polycystic ovary syndrome	3.97e-06	3.13e-05	CbGpPWpGaD
Propranolol—CYP1A2—Metabolism—CYP1A1—polycystic ovary syndrome	3.9e-06	3.08e-05	CbGpPWpGaD
Propranolol—CYP2C19—Metabolism—PPARG—polycystic ovary syndrome	3.78e-06	2.98e-05	CbGpPWpGaD
Propranolol—CYP3A4—Metabolism—CYP19A1—polycystic ovary syndrome	3.73e-06	2.94e-05	CbGpPWpGaD
Propranolol—CYP2C19—Metabolism—POMC—polycystic ovary syndrome	3.73e-06	2.94e-05	CbGpPWpGaD
Propranolol—CYP2C19—Metabolism—INS—polycystic ovary syndrome	3.71e-06	2.93e-05	CbGpPWpGaD
Propranolol—ABCB1—Metabolism—PPARG—polycystic ovary syndrome	3.69e-06	2.91e-05	CbGpPWpGaD
Propranolol—ADRB1—Signaling Pathways—VEGFA—polycystic ovary syndrome	3.68e-06	2.9e-05	CbGpPWpGaD
Propranolol—ABCB1—Metabolism—POMC—polycystic ovary syndrome	3.64e-06	2.87e-05	CbGpPWpGaD
Propranolol—CYP1A2—Metabolism—MTHFR—polycystic ovary syndrome	3.63e-06	2.87e-05	CbGpPWpGaD
Propranolol—ABCB1—Metabolism—INS—polycystic ovary syndrome	3.62e-06	2.86e-05	CbGpPWpGaD
Propranolol—ADRB2—Signaling Pathways—VEGFA—polycystic ovary syndrome	3.6e-06	2.84e-05	CbGpPWpGaD
Propranolol—HTR1A—Signaling Pathways—VEGFA—polycystic ovary syndrome	3.52e-06	2.78e-05	CbGpPWpGaD
Propranolol—CYP2D6—Metabolism—PPARG—polycystic ovary syndrome	3.48e-06	2.74e-05	CbGpPWpGaD
Propranolol—CYP2D6—Metabolism—POMC—polycystic ovary syndrome	3.43e-06	2.71e-05	CbGpPWpGaD
Propranolol—CYP2D6—Metabolism—INS—polycystic ovary syndrome	3.41e-06	2.69e-05	CbGpPWpGaD
Propranolol—CYP3A4—Metabolism—GNAS—polycystic ovary syndrome	3.33e-06	2.63e-05	CbGpPWpGaD
Propranolol—HTR1B—Signaling Pathways—IL6—polycystic ovary syndrome	3.2e-06	2.52e-05	CbGpPWpGaD
Propranolol—CYP3A4—Metabolism—NCOR1—polycystic ovary syndrome	3.17e-06	2.5e-05	CbGpPWpGaD
Propranolol—CYP3A4—Metabolism—CYP1A1—polycystic ovary syndrome	3.01e-06	2.37e-05	CbGpPWpGaD
Propranolol—CYP1A2—Metabolism—PPARG—polycystic ovary syndrome	2.95e-06	2.33e-05	CbGpPWpGaD
Propranolol—CYP1A2—Metabolism—POMC—polycystic ovary syndrome	2.91e-06	2.29e-05	CbGpPWpGaD
Propranolol—CYP1A2—Metabolism—INS—polycystic ovary syndrome	2.89e-06	2.28e-05	CbGpPWpGaD
Propranolol—CYP3A4—Metabolism—MTHFR—polycystic ovary syndrome	2.8e-06	2.21e-05	CbGpPWpGaD
Propranolol—ADRB1—Signaling Pathways—IL6—polycystic ovary syndrome	2.54e-06	2.01e-05	CbGpPWpGaD
Propranolol—ADRB2—Signaling Pathways—IL6—polycystic ovary syndrome	2.49e-06	1.96e-05	CbGpPWpGaD
Propranolol—HTR1A—Signaling Pathways—IL6—polycystic ovary syndrome	2.43e-06	1.92e-05	CbGpPWpGaD
Propranolol—CYP3A4—Metabolism—PPARG—polycystic ovary syndrome	2.27e-06	1.79e-05	CbGpPWpGaD
Propranolol—CYP3A4—Metabolism—POMC—polycystic ovary syndrome	2.24e-06	1.77e-05	CbGpPWpGaD
Propranolol—CYP3A4—Metabolism—INS—polycystic ovary syndrome	2.23e-06	1.76e-05	CbGpPWpGaD
